

# SCIENTIFIC REPORTS

OPEN

## Discovery of prenylated flavonoids with dual activity against influenza virus and *Streptococcus pneumoniae*

Received: 25 February 2016

Accepted: 16 May 2016

Published: 03 June 2016


Ulrike Grienke<sup>1,\*</sup>, Martina Richter<sup>2,\*</sup>, Elisabeth Walther<sup>2</sup>, Anja Hoffmann<sup>2</sup>, Johannes Kirchmair<sup>3</sup>, Vadim Makarov<sup>4</sup>, Sandor Nietzsche<sup>5</sup>, Michaela Schmidtke<sup>2</sup> & Judith M. Rollinger<sup>1</sup>

Influenza virus neuraminidase (NA) is the primary target for influenza therapeutics. Severe complications are often related to secondary pneumonia caused by *Streptococcus pneumoniae* (pneumococci), which also express NAs. Recently, a NA-mediated lethal synergism between influenza A viruses and pneumococci was described. Therefore, dual inhibitors of both viral and bacterial NAs are expected to be advantageous for the treatment of influenza. We investigated the traditional Chinese herbal drug sāng bái pí (mulberry root bark) as source for anti-infectives. Two prenylated flavonoid derivatives, sanggenon G (4) and sanggenol A (5) inhibited influenza A viral and pneumococcal NAs and, in contrast to the approved NA inhibitor oseltamivir, also planktonic growth and biofilm formation of pneumococci. Evaluation of 27 congeners of 5 revealed a correlation between the degree of prenylation and bioactivity. Abyssinone-V 4'-methyl ether (27) inhibited pneumococcal NA with  $IC_{50} = 2.18 \mu\text{M}$ , pneumococcal growth with  $MIC = 5.63 \mu\text{M}$ , and biofilm formation with  $MBIC = 4.21 \mu\text{M}$ , without harming lung epithelial cells. Compounds 5 and 27 also disrupt the synergism between influenza A virus and pneumococcal NA *in vitro*, hence functioning as dual-acting anti-infectives. The results warrant further studies on whether the observed disruption of this synergism is transferable to *in vivo* systems.

Influenza, an acute viral infection of the respiratory tract, causes about 3 to 5 million cases of severe illness, and about 250,000 to 500,000 deaths every year worldwide<sup>1</sup>. Influenza A virus (IAV) infections are often associated with secondary complications caused by bacterial pathogens, most commonly *Streptococcus pneumoniae* (*S. pneumoniae*)<sup>2</sup>. There is a complex interplay of IAV and *S. pneumoniae*, which have developed a lethal synergistic strategy mediated by neuraminidases (NAs)<sup>2-4</sup>. NAs are present on both pathogens. The viral NA facilitates viral reproduction and spread<sup>5,6</sup> and is an established drug target. All pneumococci produce NA NanA to access receptors on lung epithelial cells<sup>2,7,8</sup>. By cleaving sialic acids from cell surface glycoproteins, viral NA provides attachment receptors and nutrients for *S. pneumoniae* colonization and growth<sup>4,9</sup>. In turn, NanA has recently been reported to contribute to the synergism by supporting viral release when added upon infection<sup>3</sup>. Since bacterial superinfection is a major factor in influenza mortality and viral and bacterial NAs are structurally related<sup>10-12</sup>, dual inhibition of both NAs presents an innovative strategy for therapy<sup>8,13</sup>. Moreover, *S. pneumoniae* forms a bacterial biofilm which is composed of an accumulation of bacteria covered by an extracellular matrix promoting a chronic disease progress<sup>14</sup>. Hence, prevention and control of these infections is a challenge for the development of anti-infective agents.

In the last few years, several studies have reported the discovery of influenza virus neuraminidase inhibitors (NAIs) isolated from natural sources<sup>13,15,16</sup>, whereby flavonoids are the most thoroughly investigated class of

<sup>1</sup>Department of Pharmacognosy, Faculty of Life Sciences, University of Vienna, Althanstraße 14, 1090 Vienna, Austria. <sup>2</sup>Jena University Hospital, Department of Virology and Antiviral Therapy, Hans-Knoell-Strasse 2, 07745 Jena, Germany. <sup>3</sup>University of Hamburg, Center for Bioinformatics, Bundesstrasse 43, 20146 Hamburg, Germany. <sup>4</sup>A.N. Bakh Institute of Biochemistry RAS, Leninsky prospekt, 33, build. 2, Moscow, 119071, Russia. <sup>5</sup>Jena University Hospital, Center of Electron Microscopy, Ziegelmuehlenweg 1, 07743 Jena, Germany. \*These authors contributed equally to this work. Correspondence and requests for materials should be addressed to M.S. (email: michaela.schmidtke@med.uni-jena.de) or J.M.R. (email: judith.rollinger@univie.ac.at)



**Figure 1. Chemical structures of isolated mulberry root bark constituents.**

compounds<sup>16,17</sup>. Various studies have focused on their ability to inhibit either bacterial or viral NAs<sup>16</sup>. However, some of them reported a considerable quenching effect or self-fluorescence (self-FL) of flavonoids, causing false-positive results in the commonly used enzyme-based NA inhibition assays<sup>18,19</sup>. Thus, bioactivities reported for flavonoids with these testing systems should be considered with caution.

During an ongoing screening campaign for natural products active on IAV and pneumococcal NAs<sup>15,20,21</sup>, we identified the di-prenylated flavone artocarpin as dual NAI, with a distinct inhibitory activity on pneumococcal growth and biofilm formation<sup>8,13</sup>. Prenylated flavonoids occur in a comparably small number of plant families, such as Fabaceae and Moraceae.

In this follow-up study, the root bark of the white mulberry tree (*Morus alba* L.; Moraceae) was selected as a plant source containing constituents (primarily flavonoids) that share characteristic prenyl features with the previously identified antipneumococcal NAI artocarpin<sup>15,21</sup>. In traditional Chinese medicine (TCM), white mulberry root bark is known under the name sǎng bái pí, which “drains the lungs, especially heat in the lungs, thereby alleviating cough and wheezing”, suggesting a beneficial effect on symptoms related to influenza and pneumonia<sup>22</sup>. In addition to phytochemical and biological investigations of anti-infective effects of sǎng bái pí constituents, this work describes the evaluation of a series of sanggenol A (5) congeners for their ability to inhibit viral and bacterial NAs as well as their antiviral and antibacterial potency. Thereby, several complementary assays were used in combination to confirm bioactivity. The study also analyses whether the investigated compounds prevent synergism of IAV and pneumococcal NanA *in vitro*. Finally, results from in depth electron-microscopic investigations of abyssinone-V 4'-methyl ether (27), one of the most potent bacterial NAIs, which also inhibits planktonic growth of pneumococci and their biofilm formation, are reported.

## Results

Starting from a methanol extract (MAE) and a fraction enriched with prenylated constituents (MAF), seven mulberry root bark constituents were isolated by separation techniques including liquid-liquid partition, column chromatography, and high-speed counter current chromatography (HSCCC).

By using LC-MS analysis and NMR experiments, and by comparison with earlier studies<sup>23,24</sup>, the constituents were identified as sanggenon B (1), sanggenon C (2), sanggenon D (3), sanggenon G (4), sanggenol A (5), kuwanon L (6), and the 1:1 mixture of moracin O and moracin P (7) (Fig. 1). The sanggenons (1–4) and 6 can be classified as Diels-Alder adducts based on a mono- or di-prenylated flavonoid unit, whereby one prenyl residue is linked to a chalcon unit via a cyclohexane ring. Compound 5 is a di-prenylated (geranyl) tetrahydroxyflavone, and 7 is a 1:1 mixture of tricyclic fused ring systems having a benzofuran scaffold.

For providing a better basis for statements concerning the traditional use of sǎng bái pí, an aqueous decoction (MAD) was prepared. By HPLC comparison, the presence of compounds 1 to 7 was confirmed in all three multi-component mixtures (MAE, MAF, MAD; Supporting Fig. S1).

**Antimicrobial investigations of the *M. alba* root bark extract, enriched fraction and pure constituents.** The inhibitory potential of *M. alba* samples against *S. pneumoniae* and influenza virus NAs was evaluated in fluorescence (FL)-based enzyme inhibition assays and (under physiologically more relevant conditions) in hemagglutination (HA)-based assays with human erythrocytes (referred to as FL and HA assay, respectively; Table 1). The readout of the FL assay is based on the quantification of the FL signal released after cleavage

Code		IC <sub>50</sub> [ $\mu$ M; extract/fraction in $\mu$ g/mL] in FL assay against		MIC [ $\mu$ M; extract/fraction in $\mu$ g/mL] in HA assay against	
		IAV 8178/09	<i>S. pneumoniae</i> rNanA	IAV 5258/09	<i>S. pneumoniae</i> DSM20566
multi-component mixtures	MAE	n.a. <sup>a</sup>	36.6 $\pm$ 11.9	n.a. <sup>a</sup>	n.a.
	MAF	n.a. <sup>a</sup>	20.5 $\pm$ 6.23 <sup>b</sup>	n.a. <sup>a</sup>	10.0 $\pm$ 0.00
natural product isolates	1	n.a. <sup>a</sup>	15.0 $\pm$ 3.48 <sup>b</sup>	n.a. <sup>a</sup>	31.6 $\pm$ 0.00
	2	50.6 $\pm$ 4.09 <sup>b</sup>	11.3 $\pm$ 1.27 <sup>b</sup>	n.a. <sup>a</sup>	n.a. <sup>a</sup>
	3	n.a. <sup>a</sup>	3.15 $\pm$ 1.01 <sup>b</sup>	n.a. <sup>a</sup>	31.6 $\pm$ 0.00
	4	30.9 $\pm$ 6.46 <sup>b</sup>	2.91 $\pm$ 0.65	n.a. <sup>a</sup>	5.44 $\pm$ 3.95
	5	50.2 $\pm$ 4.85 <sup>b</sup>	6.22 $\pm$ 1.18	31.6 $\pm$ 0.00	31.6 $\pm$ 0.00
	6	n.a. <sup>a</sup>	8.34 $\pm$ 0.97 <sup>b</sup>	n.a. <sup>a</sup>	31.6 $\pm$ 0.00
	7	n.a. <sup>a</sup>	n.a. <sup>a</sup>	77.2 $\pm$ 39.5	100 $\pm$ 0.00
non-prenylated congeners of 5	8	n.a.	24.5 $\pm$ 0.84	n.a.	n.a.
	9	n.a. <sup>a</sup>	30.3 $\pm$ 7.02 <sup>b</sup>	n.a.	n.a.
	10	n.a. <sup>a</sup>	32.1 $\pm$ 5.66 <sup>b</sup>	n.a.	n.a.
	11	n.a. <sup>a</sup>	11.6 $\pm$ 4.45	77.2 $\pm$ 35.3	45.3 $\pm$ 30.6
	12	n.a. <sup>a</sup>	11.5 $\pm$ 1.96 <sup>b</sup>	n.a. <sup>a</sup>	72.6 $\pm$ 37.5
	13	n.a. <sup>a</sup>	55.7 $\pm$ 23.9	n.a.	n.a.
	14	n.a. <sup>a</sup>	13.8 $\pm$ 9.71 <sup>b</sup>	n.a. <sup>a</sup>	72.6 $\pm$ 37.5
	15	79.7 $\pm$ 5.34	n.a.	n.a. <sup>a</sup>	23.0 $\pm$ 11.8
	16	n.a. <sup>a</sup>	20.3 $\pm$ 1.70 <sup>b</sup>	70.7 $\pm$ 36.6	23.0 $\pm$ 11.8
	17	n.a.	24.6 $\pm$ 4.50	n.a. <sup>a</sup>	n.a.
mono-prenylated congeners of 5	18	n.a.	68.4 $\pm$ 8.82	100 $\pm$ 0.00	n.a.
	19	n.a.	9.29 $\pm$ 1.49	n.a. <sup>a</sup>	n.a. <sup>a</sup>
	20	70.3 $\pm$ 6.52	11.1 $\pm$ 4.63	n.a. <sup>a</sup>	n.a. <sup>a</sup>
	21	39.9 $\pm$ 8.38 <sup>b</sup>	15.0 $\pm$ 5.50	86.3 $\pm$ 30.6	65.8 $\pm$ 37.5
	22	n.a.	99.4 $\pm$ 59.6	100 $\pm$ 0.00	31.6 $\pm$ 0.00
	23	n.a.	83.3 $\pm$ 28.0	100 $\pm$ 0.00	31.6 $\pm$ 0.00
di-prenylated congeners of 5	24	77.4 $\pm$ 15.5	3.08 $\pm$ 2.01	20.8 $\pm$ 10.8	3.16 $\pm$ 0.00
	25	18.8 $\pm$ 2.57	3.12 $\pm$ 0.63	n.a. <sup>a</sup>	14.3 $\pm$ 9.66
	26	34.6 $\pm$ 4.41	12.6 $\pm$ 1.89	n.a. <sup>a</sup>	10.0 $\pm$ 0.00
	27	34.6 $\pm$ 4.41	2.18 $\pm$ 0.45	n.a. <sup>a</sup>	7.72 $\pm$ 3.53
	28	n.a. <sup>a</sup>	10.3 $\pm$ 2.57 <sup>b</sup>	54.4 $\pm$ 35.3	15.4 $\pm$ 10.8
	29	n.a.	24.5 $\pm$ 3.25	n.a. <sup>a</sup>	31.6 $\pm$ 0.00
	30	n.a.	10.0 $\pm$ 0.00	n.a. <sup>a</sup>	10.0 $\pm$ 0.00
	31	39.5 $\pm$ 4.36	8.00 $\pm$ 2.58	n.a. <sup>a</sup>	n.a. <sup>a</sup>
	32	37.4 $\pm$ 2.21	15.4 $\pm$ 9.71	n.a. <sup>a</sup>	10.0 $\pm$ 0.00
	33	n.a.	2.60 $\pm$ 1.20	31.6 $\pm$ 0.00	10.0 $\pm$ 0.00
	34	n.a. <sup>a</sup>	n.a. <sup>a</sup>	n.a. <sup>a</sup>	17.2 $\pm$ 12.5
	oseltamivir	0.004 $\pm$ 0.001	6.98 $\pm$ 2.44	0.002 $\pm$ 0.001	2.08 $\pm$ 1.25

**Table 1. Inhibition of influenza A virus (IAV) and *Streptococcus pneumoniae* neuraminidases (NAs) by the *M. alba* root bark methanol extract (MAE), its fraction enriched with prenylated constituents (MAF), *M. alba* isolates and congeners of sanggenol A (5).** The 50% inhibitory concentration (IC<sub>50</sub>) was determined with the IAV Jena/8178/2009 (8178/09) and recombinant NanA of the *S. pneumoniae* strain DSM20566 (rNanA) and the minimal inhibitory concentration (MIC) with IAV Jena/5258/09 (5258/09) and total protein of *S. pneumoniae* DSM20566 in fluorescence (FL)-based and hemagglutination (HA)-based NA inhibition assays, respectively. <sup>a</sup>No activity (n.a.) was found at concentrations where compounds were without self-fluorescence (Supplementary Table S1), lyse, or hemagglutinate human erythrocytes (Supplementary Table S2). <sup>b</sup>Self-fluorescence was observed (Supplementary Table S1). The highest tested concentration was 100  $\mu$ g/mL (extract/fraction) or 100  $\mu$ M (pure compounds). Means and standard deviations were determined in at least three independent experiments.

of the sialic acid-containing synthetic substrate (MUNANA) by NAs of the H1N1 influenza virus strains A/WSN/1933 (WSN/33<sup>25</sup>) and A/Jena/8178/2009 (8178/09; A(H1N1)pdm09 strain), and the recombinant NanA of pneumococcal strain DSM20566 (rNanA) at pH 6.0<sup>13</sup>. In order to rule out false positive or negative results, all samples were checked for FL quenching and self-FL as described previously (Supplementary Table S1)<sup>13</sup>. Since neither WSN/33 nor 8178/09 NA did elute agglutinated human erythrocytes, the HA assay was performed with influenza virus strain A/Jena/5258/2009 (5258/09; A(H1N1)pdm09 strain) in parallel to the NA-containing precipitate of strain DSM20566. Before evaluation of bioactivity, potential assay interferences, e.g. erythrocyte lysis,

hemagglutination of erythrocytes or, in the case of viral NAs, prevention of virus-induced hemagglutination by test compounds were ruled out (Supplementary Table S2).

As expected, oseltamivir, used as a dual-acting<sup>8,20</sup> control, inhibits IAV NAs as well as pneumococcal NAs (with a much lower activity) in the FL and HA assay. No assay interference was observed.

At the multi-component level (MAE and MAF), inhibition of viral NA was weak (Table 1 and Supplementary Table S3) or could not be investigated due to problems with assay readout (Supplementary Tables S1 and S2), which were most likely caused by the presence of assay-interfering constituents in the complex mixtures. MAE inhibited bacterial NA in the FL assay with  $IC_{50} = 36.6 \mu\text{g/mL}$ , which however could not be confirmed by the HA assay. Interestingly, the MAE fraction MAF, enriched with prenylated constituents, showed distinct inhibitory activity against pneumococcal NA in the FL assay ( $IC_{50} 20.5 \mu\text{g/mL}$ ) and the HA assay (MIC  $10.0 \mu\text{g/mL}$ ) (Table 1).

Most of the compounds isolated from MAF exerted stronger inhibitory activities against pneumococcal NA (lower values indicate stronger activity) as compared to viral NA. However, interpretation of the readouts obtained with viral NA was often hindered by self-FL in the FL assay (Supplementary Table S1) or by erythrocyte lysis and prevention of virus-induced hemagglutination in the HA assay (Supplementary Table S2). The most pronounced inhibition of the pneumococcal NA in the FL assay was observed for **3**, **4**, **5**, and **6**, with  $IC_{50}$  values of 3.1, 2.9, 6.2, and  $8.3 \mu\text{M}$ , respectively. For these compounds the inhibitory effects could be confirmed in the HA assay, with MICs of 5.4 (**4**) and  $31.6 \mu\text{M}$  (all others).

Most compounds were well tolerated by Madin-Darby canine kidney (MDCK) and A549 lung epithelial cells, whereby results determined in lung epithelial cells might be physiologically more relevant (Table 2).

The antiviral potential of the multi-component mixtures and pure constituents from *M. alba* was demonstrated in cytopathic effect (CPE) inhibitory assays with the IAV strains WSN/33 and/or 8178/09 in MDCK cells. MAE inhibited the CPE of 8178/09 or WSN/33 by 50% at concentrations of  $29.7 \mu\text{g/mL}$  and  $9.33 \mu\text{g/mL}$  (Table 2) whereas MAF acted at  $76.6 \mu\text{g/mL}$  and  $23.0 \mu\text{g/mL}$  (Supplementary Table S3), respectively. Some of its isolates reduced the 8178/09-induced (**2** and **4**) and/or WSN/33-induced CPE (**4**, **5**, and **6**) in MDCK cells, whereas the other constituents (i.e. **1**, **3**, and **7**) showed no activity in this phenotypic assay.

Concerning the general antibacterial activity of *M. alba* constituents on *S. pneumoniae*, with the exception of **1**, **6**, and **7**, all isolated compounds inhibited the planktonic growth and biofilm formation of DSM20566 at concentrations lower than  $10 \mu\text{M}$  by 90% (Table 2).

All these results together show that **4** and **5** have the most promising antiviral and antibacterial profile, which correlates with their inhibitory activity against both viral and pneumococcal NAs (with the latter being more susceptible). Since **4** exerted stronger assay interference phenomena than the geranylated flavanone **5**, the latter was selected for further investigations.

**Evaluation of anti-infective properties of congeners of sanggenol A (compound 5).** In search for further compounds with inhibitory activity on IAV and *S. pneumoniae*, a selection of off-the-shelf congeners of **5** (i.e. non-prenylated, mono-prenylated and di-prenylated compounds) (Fig. 2) was tested for their inhibitory activity on viral and bacterial NA.

In general, the tested congeners of **5** showed higher activity on the bacterial than the viral enzyme (Table 1). The structure-activity landscape is comparably flat, with the majority of tested compounds active on bacterial NA in the low micromolar range. Among the tested congeners only a few compounds can be considered as inactive, i.e. **15**, **22** and **23** (FL assay). Activity appears to increase with the degree of prenylation and hence, hydrophobicity. In particular the di-prenylated compounds **24** and **27** exerted strong bacterial NA inhibitory activities in the FL as well as the HA assay.

Alignment of bioactive congeners on their flavonoid scaffold suggests that bulky substituents may be attached to several positions of the scaffold without a consistent loss of bioactivity (data not shown). This renders a common binding mode for this chemical series in proximity of the substrate binding site improbable. No co-crystal of a flavonoid bound with NA has been reported to date, to the best of our knowledge. From a docking experiment with compound **5** on a homology model of NanA (using Glide<sup>26</sup>), varying orientations of the ligand were obtained, some of which with the flavonoid scaffold placed at the substrate binding site and others with the lipophilic geranyl moiety oriented toward it (data not shown). The results from this docking experiment were inconclusive, and all observations considered together indicate that **5** and its congeners are unlikely to share a single binding mode. Rather, the observed inhibitory activity may be the result of interactions related to the compatibility of the physicochemical properties of ligand and protein, with hydrophobic interactions playing a significant role.

With the exception of **18** (WSN/33 and 8178/09) and **23** (8178/09), none of the tested compounds inhibited the virus-induced CPE in MDCK cells at non-cytotoxic concentrations. However, compound **27** significantly reduced the virus yield of untreated virus control, set as 100%, to  $7.4 \pm 1.2\%$  in A549 cells after treatment with  $50 \mu\text{M}$  of **27**. This concentration could not be tested in MDCK cells due to cytotoxicity concerns. In accordance with mentioned antibacterial NA activities, strong anti-pneumococcal effects were observed especially for di-prenylated congeners of compound **5**.

**Confirmation of biofilm inhibition by compound 27 using scanning electron microscopy studies.**


To visualise the effect of di-prenylated congeners of **5** on biofilm formation of pneumococci, scanning electron microscopy was applied. After establishing the experimental conditions for biofilm production of the pneumococcal strain DSM20566 on glass slides, bacteria were treated with **27**, one of the strongest inhibitors of bacterial NA and bacterial biofilm formation. DSM20566 pneumococci were treated with medium (mock-treated) and  $10 \mu\text{M}$  of oseltamivir (virus-specific NAI) or **27**, for 7 days, starting 3 h after inoculation of bacteria (the time necessary for the attachment of pneumococci to glass slides). At the end of the incubation time a distinct

Code		CC <sub>50</sub> [μM; extract/fraction in μg/mL] in		IC <sub>50</sub> [μM; extract/fraction in μg/mL] of CPE	MIC <sub>90</sub> [μM; extract/fraction in μg/mL]	MBIC <sub>90</sub> [μM; extract/fraction in μg/mL]
		MDCK cells	A549 cells	IAV 8178/09	<i>S. pneumoniae</i> DSM20566	<i>S. pneumoniae</i> DSM20566
multi-component mixtures	MAE	>100 <sup>a</sup>	>100 <sup>a</sup>	29.7 ± 3.35	n.d.	n.d.
	MAF	75.2 ± 0.81	77.6 ± 15.5	9.33 ± 0.11	n.d.	n.d.
natural product isolates	1	28.1 ± 7.26	32.0 ± 9.16	n.a.	35.2 ± 14.8	11.5 ± 0.54
	2	51.7 ± 12.2	32.6 ± 9.07	8.30 ± 0.70	2.73 ± 0.35	1.08 ± 0.39
	3	99.0 ± 8.70	79.9 ± 11.2	n.a.	8.72 ± 3.51	5.89 ± 0.20
	4	>100 <sup>a</sup>	72.9 ± 17.2	8.78 ± 0.89	5.81 ± 4.44	1.55 ± 0.36
	5	42.1 ± 4.45	>100 <sup>a</sup>	n.a.	5.05 ± 1.56	4.44 ± 1.47
	6	>100 <sup>a</sup>	94.4 ± 4.73	n.a.	48.5 ± 1.34	23.0 ± 0.87
	7	80.8 ± 22.2	>100 <sup>a</sup>	n.a.	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
non-prenylated congeners of 5	8	>100 <sup>a</sup>	>100 <sup>a</sup>	>100 <sup>a</sup>	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	9	36.0 ± 23.4	35.0 ± 4.60	n.a.	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	10	>100 <sup>a</sup>	>100 <sup>a</sup>	>100 <sup>a</sup>	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	11	>100 <sup>a</sup>	>100 <sup>a</sup>	78.3 ± 5.72	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	12	>100 <sup>a</sup>	>100 <sup>a</sup>	>100 <sup>a</sup>	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	13	>100 <sup>a</sup>	>100 <sup>a</sup>	>100 <sup>a</sup>	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	14	>100 <sup>a</sup>	>100 <sup>a</sup>	>100 <sup>a</sup>	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	15	23.0 ± 0.18	>100 <sup>a</sup>	n.a.	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	16	>100 <sup>a</sup>	>100 <sup>a</sup>	70.1 ± 9.83	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
mono-prenylated congeners of 5	17	>100 <sup>a</sup>	>100 <sup>a</sup>	>100 <sup>a</sup>	>50.0 <sup>a</sup>	>50.0 <sup>a</sup>
	18	59.2 ± 15.0	>100 <sup>a</sup>	25.9 ± 3.67	22.4 ± 1.37	23.5 ± 0.34
	19	50.5 ± 6.32	>100 <sup>a</sup>	n.a.	99.6 ± 0.23	5.91 ± 0.13
	20	67.9 ± 2.62	>100 <sup>a</sup>	n.a.	11.6 ± 0.15	17.2 ± 4.50
	21	64.9 ± 1.28	>100 <sup>a</sup>	n.a.	34.9 ± 12.5	35.5 ± 8.87
	22	63.4 ± 8.31	>100 <sup>a</sup>	n.a.	12.1 ± 0.59	40.2 ± 9.17
	23	69.0 ± 3.56	>100 <sup>a</sup>	24.7 ± 4.55	42.2 ± 3.96	46.5 ± 1.46
	24	60.6 ± 3.81	>100 <sup>a</sup>	n.a.	>50.0 <sup>a</sup>	49.0 ± 1.25
di-prenylated congeners of 5	25	55.8 ± 4.41	>100 <sup>a</sup>	n.a.	9.07 ± 3.65	11.2 ± 0.91
	26	42.2 ± 22.6	63.2 ± 25.9	n.a.	7.28 ± 4.14	8.66 ± 2.35
	27	2.29 ± 0.10	>100 <sup>a</sup>	n.a.	5.63 ± 0.52	4.21 ± 1.45
	28	15.8 ± 7.58	59.1 ± 19.8	n.a.	2.89 ± 0.07	3.08 ± 0.03
	29	34.0 ± 7.96	80.6 ± 2.47	n.a.	11.9 ± 0.34	22.2 ± 0.25
	30	21.1 ± 0.91	48.8 ± 16.0	n.a.	9.43 ± 8.38	5.91 ± 0.46
	31	20.0 ± 1.53	47.1 ± 2.83	n.a.	8.82 ± 3.55	8.77 ± 1.84
	32	21.4 ± 0.73	79.6 ± 2.77	n.a.	3.16 ± 0.43	4.55 ± 0.69
	33	33.4 ± 21.4	41.7 ± 14.6	n.a.	5.24 ± 0.30	3.77 ± 1.39
	34	0.63 ± 0.04	60.4 ± 16.8	n.a.	15.1 ± 7.40	>50.0 <sup>a</sup>


**Table 2. Cytotoxicity, anti-influenza A virus (IAV), and anti-*Streptococcus pneumoniae* activity of *M. alba* root bark methanol extract (MAE), its fraction enriched with prenylated constituents (MAF), *M. alba* isolates and congeners of sanggenol A (5). Their 50% cytotoxic concentration (CC<sub>50</sub>) in Madin-Darby canine kidney (MDCK) cells and in human lung carcinoma cells (A549), their 50% inhibition concentration (IC<sub>50</sub>) determined against IAV Jena/8178/2009 (8178/09) in cytopathic effect (CPE) inhibition assay in MDCK cells as well as their effect on pneumococcal (strain DSM20566) growth (MIC<sub>90</sub> = 90% minimal inhibitory concentration) and biofilm formation (MBIC<sub>90</sub> = 90% minimal biofilm inhibitory concentration) is presented. <sup>a</sup>highest concentration tested. Means and standard deviation of the extracts and compounds based on minimum of three independent assays. n.a., not active at noncytotoxic concentrations in MDCK cells (used in CPE inhibitory assay). n.d., not determined.**

pneumococcal biofilm was formed on mock-treated slides with typical bacteria clusters crisscrossed by water channels (Fig. 3A,D). Oseltamivir treatment did not impair biofilm formation (Fig. 3B,E). In contrast, treatment of pneumococci with compound 27 completely prevented biofilm formation and induced the death of bacteria (Fig. 3C,F).

The time-dependent antibacterial effect of 27 was studied to determine whether the compound acts on bacteria during biofilm formation and/or the developed pneumococcal biofilm. Therefore, treatment with 10 μM of 27 was started (i) directly after the attachment of single pneumococci to the glass surface at three hours after inoculation of bacteria (an example for attached bacteria is shown for control in Fig. 4A), (ii) at two time points during biofilm growth (six or nine hours after inoculation of bacteria), or (iii) when the biofilm was formed




**Figure 2.** Chemical structures of non- (A), mono- (B), and di-prenylated (C) congeners of 5.



**Figure 3.** Effect of oseltamivir and compound 27 on pneumococcal biofilm formation. Three hours after inoculation of bacteria onto glass slides in 24-well plates the supernatant was replaced with fresh medium containing no inhibitor (A,D), 10  $\mu$ M of oseltamivir (B,E) or 10  $\mu$ M of compound 27 (C,F). Bacteria were incubated at 37  $^{\circ}$ C and 5% CO<sub>2</sub> for 7 days and afterwards analysed by scanning electron microscopy. The experiment was performed twice. Representative photographs are shown.

(48 hours after inoculation of the bacteria). After 7 days of incubation a biofilm was formed in mock-treated wells, confirming the results of the first experiment (Fig. 4B). A strong effect was confirmed when 27 was added three hours after inoculation of bacteria (Fig. 4C). When the treatment with 27 started six hours after inoculation of bacteria, no biofilm was formed (Fig. 4D). The addition of compound 27 nine hours after bacteria inoculation affected biofilm formation weakly (Fig. 4E). Late treatment (i.e. 48 h after bacteria inoculation) had no effect (Fig. 4F). The scanning electron microscopy studies confirmed the inhibitory effect of 27 on biofilm formation of *S. pneumoniae*.

**Compounds 5 and 27 disrupt the synergism between viral and *S. pneumoniae* NA *in vitro*.** Due to structural and functional similarities to viral NA<sup>12,16</sup>, the ubiquitously expressed NanA in *S. pneumoniae*<sup>7,8,27</sup> supports influenza virus release from infected cells<sup>3</sup>. Moreover, results from previous studies showed that bacterial



**Figure 4. Time-dependent inhibition of pneumococcal biofilm formation by compound 27.** Three hours after inoculation of bacteria in 24-well plates, bacteria were fixed (control, (A)). The supernatant of other wells was replaced by fresh medium containing no inhibitor (B) or 10  $\mu\text{M}$  of 27 (C–F). Three (C), six (D), nine (E) or 48 h (F) after inoculation, 27 was added to the medium to reach a concentration of 10  $\mu\text{M}$  in the supernatant. Bacteria were incubated at 37  $^{\circ}\text{C}$  and 5%  $\text{CO}_2$  for 7 days and afterwards analysed by scanning electron microscopy.

NA rescues influenza virus replication from inhibition by zanamivir<sup>3,28</sup>. In contrast, both 5 and 27 (50  $\mu\text{M}$ ) reduce the viral yield in A549 cells in the presence of NanA of DSM20566 from 100 to  $31.8 \pm 4.5\%$  and  $7.4 \pm 1.2\%$ . These results are in good agreement with the virus yield reduction in the absence of NanA (reduction to  $5.1 \pm 1.8\%$  and  $3.2 \pm 1.4\%$ ). Hence, both 5 and 27 prevent the synergism of viral and pneumococcal NAs in A549 cells.

## Discussion

Since bacterial co-infection in influenza patients indicates a strong detrimental interaction between pneumococci and IAVs, targeting these two pathogens in parallel appears to be a promising avenue for the development of highly effective therapeutics. Thereby, addressing the issue of secondary pneumonia could also enhance the value of influenza prevention and treatment. Structural similarities of the surface protein NA, present on both *S. pneumoniae* and IAVs, render this enzyme a key target in this effort.

In this study, the flavonoid-rich TCM herbal drug sāng bái pí (white mulberry root bark) has been investigated from different angles (NA inhibition, cytotoxicity, anti-AIV and anti-*S. pneumoniae* activities, inhibition of viral replication in the presence of bacterial NAs) with different assay systems (both target- and cell-based) as potential source for natural anti-influenza virus and antipneumococcal compounds.

Our studies started from multicomponent mixtures (MAE and MAF). Earlier interference problems observed with NA assays prompted us to establish and apply a panel of complementary target-based and cell-based assays (Supplementary Tables S1 and S2). This panel allowed us to identify and confirm the distinct inhibitory activity of a fraction enriched with prenylated constituents (MAF) against the NA of pneumococci (Table 1) and influenza A viruses (Table 2 and Supplementary Table S3).

Among the compounds isolated from sāng bái pí multicomponent mixtures, the prenylated flavonoid derivatives 4 and 5 (Fig. 1) inhibited viral and pneumococcal NAs, pneumococcal growth and biofilm formation in the low micromolar range (Tables 1 and 2). As a herbal remedy against upper respiratory tract infections sāng bái pí is traditionally applied as decoction based on formulations containing several further plant materials, thereby, often relying on synergistic effects of their components. This makes scientific investigations of the active principle challenging. Because of our focus on prenylated flavonoids, compounds 1 to 7 were isolated in a target-oriented approach from a methanol extract (MAE) and its bioactive fraction, MAF. However, we also identified 1 to 7 as constituents in the aqueous decoction of sāng bái pí (MAD), not ruling out their involvement in the bioactivity of the traditional application form.

Follow-up studies with 27 congeners of 5 (non-, mono-, and di-prenylated; Fig. 2) revealed a direct correlation between the degree of prenylation and bioactivity. In full agreement with previously published data<sup>8</sup>, oseltamivir does neither inhibit planktonic growth nor biofilm formation of *S. pneumoniae* (Tables 1 and 2), despite its inhibitory activity on viral NA. In contrast, we observed a correlation between inhibitory activity on bacterial NA, bacterial growth and biofilm formation for compound 5 (and some of its di-prenylated congeners). However, a causative relationship between the inhibition of NA, bacterial growth and/or biofilm formation could not be conclusively established.

Congeners of 5 showed consistent, potent activities in all different types of *in vitro* assays. Compound 27 inhibited both viral and pneumococcal NA; it reduced IAV replication in presence and absence of NanA, *S. pneumoniae* growth in suspension, and biofilm formation. Whether di-prenylated congeners effectively engage in the complex interactions between IAV and pneumococci *in vivo* will require further studies in superinfection models.

The data accumulated so far indicate that the investigated di-prenylated flavonoids could serve as a promising starting point for the development of new therapeutics able to disrupt the lethal synergism between IAV and *S. pneumoniae*.

## Methods

**Plant material.** White mulberry root bark (in China also known under the name *sāng bái pí*) is the dried root bark of *Morus alba* L. (Moraceae). The material used for this study was purchased from Plantasia, Oberndorf, Austria. In TCM, the root is collected in late autumn while the leaves are falling off and in early spring before germination. It is removed from the yellowish-brown coarse bark and cut longitudinally. The root bark is stripped off and dried in the sun. The material's quality and identity was macroscopically (appearance, texture, odour, taste, etc.) and microscopically (transverse section) checked according to the monograph "*sāng bái pí*" of the Pharmacopoeia of the Peoples Republic of China<sup>29</sup>. Voucher specimens (JR-20090112-A1) are deposited in the Herbarium of the Department of Pharmacognosy, University of Vienna, Austria.

**Extraction, isolation, and identification of pure compounds.** Dried ground root bark of *M. alba* (2 kg) was macerated with methanol (7 L at 22 °C for 7 days). For an exhaustive extraction the procedure was repeated three times. The dried extract (MAE, 168.6 g) was separated by liquid-liquid partition into a methanol-water phase (CH<sub>3</sub>OH-H<sub>2</sub>O 1:1) and a petroleum ether phase (PE). The dried CH<sub>3</sub>OH-H<sub>2</sub>O phase (111.4 g) was roughly fractionated by silica gel CC (Merck silica gel 60 PF254, 350 g; 12.5 × 20 cm) using a step gradient of CH<sub>2</sub>Cl<sub>2</sub>-CH<sub>3</sub>OH-acetone (CH<sub>2</sub>Cl<sub>2</sub>; CH<sub>2</sub>Cl<sub>2</sub>-CH<sub>3</sub>OH 95:5; 90:10; 75:25; 50:50; 34:67; 25:75; 10:90; CH<sub>3</sub>OH; CH<sub>3</sub>OH-acetone 1:1; acetone) to give six fractions (A1-6). Fraction A4 (MAE, 15.32 g) was separated by High Speed Counter Current Chromatography (HSCCC, Pharma Tech Research PTR) (flow rate 1.0 mL/min) using CHCl<sub>3</sub> as stationary phase and CH<sub>3</sub>OH-H<sub>2</sub>O as the mobile phase (CHCl<sub>3</sub>-CH<sub>3</sub>OH-H<sub>2</sub>O; 4:4:3) obtaining twenty fractions B1-20. Fraction B8 yielded the purified compound **3** (140.86 mg), and fraction B16 the pure compound **2** (160.25 mg). The combined fraction of B11-13 (130.12 mg) enriched with **4** and **6** was fractionated by liquid CC (Merck Lobar; pre-packed column size A (240-10); LiChroprep RP-18, 40–63 μm; H<sub>2</sub>O/acetonitrile from 70:30 to 60:40 within 24.0 min to 30:70 in another 64 min; from 30:70 to 2:98 within 4.0 min; isocratic 2:98 for 20.0 min) to afford pure compounds **4** (37.34 mg) and **6** (48.52 mg).

A3 (2.05 g) was fractionated via a Sephadex LH-20 (Pharmacia Biotech, Sweden; 1.5 × 100 cm) column with CH<sub>3</sub>OH as mobile phase to gain eighteen fractions D1-18. D14 (62.48 mg) was further separated by Lobar (column size A (240-10); LiChroprep RP-18, 40–63 μm) using H<sub>2</sub>O/acetonitrile as mobile phase (v/v; isocratic 65:35 for 5.0 min; from 65:35 to 40:60 within 60.0 min to 2:98 in another 60.0 min) to give 14.28 mg of **7** (14.28 mg). D12 (210.09 mg) and D13 (91.70 mg) were also separated by Lobar (column size A (240-10); LiChroprep RP-18, 40–63 μm; water/acetonitrile isocratic 40:60 for 12.0 min; from 40:60 to 25:75 within 60.0 min; isocratic 25:75 for 60.0 min; from 25:75 to 2:98 within 60.0 min) to yield the pure compound **1** (22.85 mg) and **5** (38.52 mg).

All isolated compounds (**1** to **7**) were identified by 1D and 2D NMR experiments (Bruker TXI600 NMR spectrometer operating at 600 MHz). The spectroscopic data of compounds **1** to **7** agreed with those published previously for sanggenon B (**1**), sanggenon C (**2**), sanggenon D (**3**), sanggenon G (**4**), sanggenol A (**5**), kuwanon L (**6**), and the 1:1 mixture of moracin O and moracin P (**7**)<sup>30–37</sup>. Their purity was checked using TLC and LC-MS (Bruker-Daltonics Esquire 3000 plus ion trap) and determined as >95% in all cases.

### Preparation of *sāng bái pí* water decoction (MAD) and HPLC comparison of MAD, MAE and MAF.

Dried ground root bark of *M. alba* (10 g) was soaked exhaustively with cold water (0.5 L) for 1 h. Subsequently the material was decocted for 20 min in a pot with a lid. After filtration through cotton wool, the decoction procedure was repeated with the remaining plant material. The filtrated decoctions were combined (MAD) and an aliquot was used for HPLC analyses. HPLC of MAE, MAF, and MAD (Supplementary Fig. 1) was performed on a Shimadzu device consisting of an LC-10ADV solvent delivery system, a FCV-10ALVP low-pressure gradient flow control valve, an SCL-10AVP system controller, a DGU-14A degasser, and a SPD-M20A photodiode array (PDA) detector. LC-parameters: stationary phase: Agilent Zorbax SB-C18 3.5 μm (150 × 4.6 mm); temperature: 25 °C; mobile phase: A = water; B = acetonitrile; flow rate 1.0 mL/min; PDA detection wavelength: 205 nm; injection volume: 10 μL; Separations were performed by gradient elution (70/30 A/B in 5 min to 55/45 A/B, then within 15 min to 45/55 A/B, and within 2 min to 2/98 A/B), followed by a 10 min column wash (2A/98B) and a re-equilibration period of 10 min. All chemicals and solvents used were analytical grade.

**Sanggenol A (5) congeners.** Congeners of **5** were purchased from AnalytiCon Discovery GmbH, Potsdam, Germany. The purity of the compounds was ≥95%, except for **20**, **12**, and **26** where it was between 70–85%, as stated and certified by the vendor. Purity was determined by HPLC-ELSD or NMR.

**Cells, viruses, and bacteria.** Madin-Darby canine kidney (MDCK) cells (Cat.nr. RIE 328, Friedrich-Loeffler Institute, Riems, Germany) were grown in Eagle's minimum essential medium (EMEM), supplemented with 10% fetal bovine serum, 1% non-essential amino acids, 1 mM sodium pyruvate and 2 mM L-glutamine (Lonza, Basel, Switzerland). Serum-free EMEM containing 2 mM L-glutamine, 2 μg/mL trypsin and 0.1% sodium bicarbonate was used in antiviral assays. Human lung carcinoma cells (A549; Institute of Molecular Virology, University of Münster, Germany) were maintained in Dulbecco's Modified Eagle Medium (Lonza Group Ltd, Basel, Switzerland), supplemented with 10% fetal calf serum (PAA Laboratories GmbH, Cölbe, Germany). Cells were cultivated at 37 °C with 5% CO<sub>2</sub>.

H1N1 influenza virus WSN/33 (amantadin-sensitive<sup>25</sup>) and A/Jena/8178/2009 (8178/09) were applied in the fluorescence (FL)-based neuraminidase (NA) inhibition (FL assay) as well as in the cytopathic effect (CPE) inhibition assay. Strain 8178/09 was additionally used to study the inhibitory effect of neuraminidase inhibitors



(NAIs) in the presence and absence of bacterial neuraminidase (NA) in A549 cells. The hemagglutination-based NA inhibition assay (HA assay) was performed with Jena/5258<sup>38</sup>.

Reference strain DSM20566 (serotype 1; ATCC 33400, Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Heidelberg, Germany) was grown on Columbia blood agar plates supplemented with 5% sheep blood (Becton Dickinson GmbH, Heidelberg, Germany) at 37 °C in an atmosphere enriched with 5% CO<sub>2</sub> overnight. During pre-cultivation, bacteria were grown in brain heart infusion (BHI) broth<sup>8</sup>.

**Enzyme inhibition assays.** The FL assay was performed as described recently<sup>13</sup> using the substrate 20-(4-methylumbelliferyl)-a-D-N-acetylneuraminic acid (MUNANA). The inhibition of the NA of whole 8178/09 and WSN/33 preparations and recombinant NanA of pneumococcus DSM20566<sup>3</sup> were studied. The readout was performed with a microplate reader (FLUOstar Omega, BMG Labtech GmbH, Ortenberg, Germany). The highest tested compound concentration was 100 μM. The 50% inhibitory concentration (IC<sub>50</sub>) values were calculated with the JASPR curve fitting software<sup>39</sup>. A minimum of three independent experiments was conducted to calculate means and standard deviations.

The inhibitory effects of the studied compounds on viral NA (Jena/5258) and pneumococcal NA (precipitated bacterial proteins of DSM20566) were also evaluated with HA assays, which were described recently<sup>13</sup>. In the viral HA assay, hemagglutinin of strain 5258/09 agglutinates human erythrocytes at 4 °C. The elution of agglutinated erythrocytes by the viral NA activity at 37 °C can be blocked by inhibitors<sup>13</sup>. Strain 5258/09 had to be used because neither WSN/33 nor 8178/09 were able to elute agglutinated erythrocytes. In the bacterial HA assay, the NA of DSM20566 cleaved sialic acid at the cell membrane, thereby providing binding sites for peanut lectin. Binding of lectin leads to hemagglutination of erythrocytes. Inhibition of pneumococcal NAs circumvents hemagglutination<sup>13</sup>.

Oseltamivir carboxylate GS4071 (oseltamivir; Roche AG, Basel, Switzerland) was included as reference compound in both assays. It was dissolved in water as 10 mM stock solutions.

**Determination of cytotoxicity and antiviral activity.** The 50% cytotoxic concentration (CC<sub>50</sub>) was determined on two-day-old confluent MDCK and three-day-old A549 cell monolayers grown on 96-well plates 72 h after adding the test compounds (maximum tested concentration: 100 μM; threefold dilutions) as described previously<sup>8,40</sup>. Cytopathic effect (CPE) inhibition was measured 48 h after 8178/09 and WSN/33 infection when a multiplicity of infection of 0.01/TCID<sub>50</sub> (50% tissue culture infection dose) per cell resulted in a complete CPE of untreated MDCK cells. Same concentrations as in cytotoxicity assay were studied. The testing conditions were published in detail earlier<sup>40</sup>. The experimental conditions for antiviral experiments without and with pneumococcal NanA in A549 cells were described recently<sup>3</sup>.

The mean CC<sub>50</sub> and IC<sub>50</sub> values and standard derivations were calculated from at least 3 individual experiments.

**Inhibition of bacterial planktonic growth and biofilm formation.** Broth microdilution assay and biofilm assay were conducted as described previously<sup>8</sup>. Briefly, pneumococci of McFarland 0.5 (1.5 × 10<sup>8</sup> colony forming unit (cfu)/mL) were 50× diluted in brain heart infusion broth (BHI), for microdilution assay. Compounds were mixed with bacteria in a 96-well V-shape plate and incubated overnight at 37 °C with 5% CO<sub>2</sub>. The highest compound concentration tested was 50 μM (twofold dilutions). The growth of bacteria was monitored by measuring optical density at 620 nm. The minimal inhibitory concentration (MIC<sub>90</sub>) was defined as the drug concentration that reduced 90% turbidity of the untreated bacterial suspension.

For the biofilm assay, broth was diluted 50-fold in tryptic soy broth and incubated for 2 h at 37 °C with 5% CO<sub>2</sub> in 96-well F-bottom plates. Then, the supernatant was replaced by 200 μL of fresh medium without or with compound (maximum 50 μM; each concentration in duplicate). After 24 h incubation, plates were washed with water and stained with crystal violet overnight. After rinsing the plates with water, the crystal violet was eluted with lysis buffer<sup>40</sup>, and the optical density of the elution was measured at 550 nm. Minimal biofilm inhibitory concentration (MBIC<sub>90</sub>) was defined as the drug concentration reducing the optical density of untreated controls by 90%.

**Scanning electron microscopy studies.** Overnight plate cultures of DSM20566 were inoculated in tryptic soy broth (TSB) and grown to mid-logarithmic phase at 37 °C in 5% CO<sub>2</sub>. Bacteria were diluted in TSB to McFarland 0.5 (~1.5 × 10<sup>8</sup> cfu/mL) and inoculated onto glass slides (diameter of 12 mm) placed on the floor of wells of a 24-well plate. Three hours after inoculation supernatant was replaced by fresh medium without or with 27 or oseltamivir (both 10 μM). Then bacteria were incubated at 37 °C and 5% CO<sub>2</sub> for 7 d. After fixation with 2.5% glutaraldehyde in cacodylate buffer (0.1 M, pH 7.2) for 24 h, the glass slides with bacteria were washed three times with cacodylate buffer and dehydrated with ascending ethanol concentrations (10, 30, 50, 70, 90, and 100%). Subsequently, the samples were critical-point dried using liquid CO<sub>2</sub> (CPD 300, Leica, Wetzlar, Germany) and gold sputtered (SCD 005, BAL-TEC, Liechtenstein) to prevent surface charging. Finally, the samples were examined with a field emission gun scanning electron microscope LEO-1530 (Zeiss, Oberkochen, Germany). For studying the time-dependent inhibitory effect on biofilm formation, 27 was added to the medium at 3, 6, 9 or 48 h after DSM20566 inoculation.

**Statistical analyses.** Mean and standard deviation (SD) values were analysed using Microsoft Excel 2010. In the studies on the interference of small molecules with the FL assay the cut-off value was set at mean ± 2 SD of control (without compound). Statistically significant differences were analysed by using Welch's t-test (Microsoft Excel).

## References

1. WHO Influenza Fact Sheets. (2015) Available at: <http://www.who.int/mediacentre/factsheets/fs211/en/>. (Accessed: 31st December 2015).
2. McCullers, J. A. The co-pathogenesis of influenza viruses with bacteria in the lung. *Nat. Rev. Microbiol.* **12**, 252–262 (2014).
3. Walther, E. *et al.* Dual-acting neuraminidase inhibitors open new opportunities to disrupt the lethal synergism between *Streptococcus pneumoniae* and influenza viruses. *Front. Microbiol.* **7**, 357 (2016).
4. Siegel, S. J., Roche, A. M. & Weiser, J. N. Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source. *Cell Host Microbe* **16**, 55–67 (2014).
5. Gong, J. Z., Xu, W. F. & Zhang, J. Structure and functions of influenza virus neuraminidase. *Curr. Med. Chem.* **14**, 113–122 (2007).
6. Air, G. M. Influenza neuraminidase. *Influenza Other Respir. Viruses* **6**, 245–256 (2012).
7. Pettigrew, M. M., Fennie, K. P., York, M. P., Daniels, J. & Ghaffar, F. Variation in the presence of neuraminidase genes among *Streptococcus pneumoniae* isolates with identical sequence types. *Infect. Immun.* **74**, 3360–3365 (2006).
8. Walther, E. *et al.* Antipneumococcal activity of neuraminidase inhibiting artocarpin. *Int. J. Med. Microbiol.* **305**, 289–297 (2015).
9. Mina, M. J., McCullers, J. A. & Klugman, K. P. Live attenuated influenza vaccine enhances colonization of *Streptococcus pneumoniae* and *Staphylococcus aureus* in mice. *mBio* **5**(1), e01040–13, doi: 10.1128/mBio.01040-13 (2014).
10. Crennell, S. J., Garman, E. F., Laver, W. G., Vimr, E. R. & Taylor, G. L. Crystal structure of a bacterial sialidase (from *Salmonella typhimurium* LT2) shows the same fold as an influenza virus neuraminidase. *Proc. Natl. Acad. Sci. USA* **90**, 9852–9856 (1993).
11. Roggentin, P. *et al.* Conserved sequences in bacterial and viral sialidases. *Glycoconjugate J.* **6**, 349–353 (1989).
12. von Grafenstein, S. *et al.* Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. *J. Biomol. Struct. Dyn.* **33**, 104–120 (2015).
13. Richter, M. *et al.* Complementary assays helping to overcome challenges for identifying neuraminidase inhibitors. *Future Virol.* **10**, 77–88 (2015).
14. Buommino, E., Scognamiglio, M., Donnarumma, G., Fiorentino, A. & D'Arosca, B. Recent advances in natural product-based anti-biofilm approaches to control infections. *Mini-Rev. Med. Chem.* **14**, 1169–1182 (2014).
15. Kirchmair, J. *et al.* Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode. *Future Med. Chem.* **3**, 437–450 (2011).
16. Grienke, U. *et al.* Influenza neuraminidase: a druggable target for natural products. *Nat. Prod. Rep.* **29**, 11–36 (2012).
17. Costa, S. S. *et al.* Flavonoids in the therapy and prophylaxis of flu: a patent review. *Expert Opin. Ther. Pat.* **22**, 1111–1121 (2012).
18. Chamni, S. & De-Eknankul, W. Recent progress and challenges in the discovery of new neuraminidase inhibitors. *Expert Opin. Ther. Pat.* **23**, 409–423 (2013).
19. Kongkamnerd, J. *et al.* The quenching effect of flavonoids on 4-methylumbelliferone, a potential pitfall in fluorimetric neuraminidase inhibition assays. *J. Biomol. Screen.* **16**, 755–764 (2011).
20. Grienke, U. *et al.* Computer-guided approach to access the anti-influenza activity of licorice constituents. *J. Nat. Prod.* **77**, 563–570 (2014).
21. Grienke, U. *et al.* Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from *Alpinia katsumadai*. *J. Med. Chem.* **53**, 778–786 (2010).
22. Bensky, D., Clavey, S. & Stöger, E. *Chinese herbal medicine: Materia medica*. 3rd edn, (Eastland Press, 2004).
23. Rollinger, J. M. *et al.* *Venturia inaequalis*-inhibiting Diels-Alder adducts from Morus root bark. *J. Agr. Food Chem.* **54**, 8432–8436 (2006).
24. Rollinger, J. M. *et al.* Discovering COX-inhibiting constituents of Morus root bark: Activity-guided versus computer-aided methods. *Planta Med.* **71**, 399–405 (2005).
25. Schade, D. *et al.* Zanamivir amidoxime- and N-hydroxyguanidine-based prodrug approaches to tackle poor oral bioavailability. *J. Pharm. Sci.* **104**, 3208–3219 (2015).
26. Friesner, R. A. *et al.* Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *J. Med. Chem.* **47**, 1739–1749 (2004).
27. King, S. J., Whatmore, A. M. & Dowson, C. G. NanA, a neuraminidase from *Streptococcus pneumoniae*, shows high levels of sequence diversity, at least in part through recombination with *Streptococcus oralis*. *J. Bacteriol.* **187**, 5376–5386 (2005).
28. Nishikawa, T. *et al.* Bacterial neuraminidase rescues influenza virus replication from inhibition by a neuraminidase inhibitor. *PLoS one* **7**, e45371 (2012).
29. Chinese Pharmacopoeia Commission *Pharmacopoeia of the People's Republic of China* 9th edn, Chemical Industry Press, Beijing, China (2010).
30. Hano, Y., Itoh, M., Fukai, T., Nomura, T. & Urano, S. Revised structure of sanggenon B. *Heterocycles* **23**, 1691–1696 (1985).
31. Nomura, T., Fukai, T., Hano, Y. & Uzawa, J. Structure of sanggenon C, a natural hyposensitive Diels-Alder adduct from Chinese crude drug “SANG-BAI-PI” (Morus root barks). *Heterocycles* **16**, 2141–2148 (1981).
32. Nomura, T., Fukai, T., Hano, Y. & Uzawa, J. Structure of sanggenon D, a natural hyposensitive Diels-Alder adduct from Chinese crude drug “SANG-BAI-PI” (Morus root barks). *Heterocycles* **17**, 381–389 (1982).
33. Fukai, T., Hano, Y., Fujimoto, T. & Nomura, T. Structure of sanggenon G, a new Diels-Alder adduct from the Chinese crude drug “SANG-BAI-PI” (Morus root barks). *Heterocycles* **20**, 611–615 (1983).
34. Fukai, T. *et al.* Isoprenylated flavanones from *Morus cathayana*. *Phytochemistry* **47**, 273–280 (1998).
35. Hano, Y., Suzuki, S., Kohno, H. & Nomura, T. Absolute configuration of kuwanon L, a Diels-Alder type adduct from the Morus root bark. *Heterocycles* **27**, 75–82 (1988).
36. Hano, Y., Suzuki, S., Nomura, T. & Iitaka, Y. Absolute configuration of natural Diels-Alder type adducts from the Morus root bark. *Heterocycles* **27**, 2315–2326 (1988).
37. Kaur, N. *et al.* The first total synthesis of moracin O and moracin P, and establishment of the absolute configuration of moracin O. *Chem. Commun.* 1879–1881, doi: 10.1039/B823340C (2009).
38. Schade, D. *et al.* Development of novel potent orally bioavailable oseltamivir derivatives active against resistant influenza A. *J. Med. Chem.* **57**, 759–769 (2014).
39. Okomo-Adhiambo, M. *et al.* Host cell selection of influenza neuraminidase variants: Implications for drug resistance monitoring in A(H1N1) viruses. *Antivir. Res.* **85**, 381–388 (2010).
40. Schmidtke, M., Schnittler, U., Jahn, B., Dahse, H. & Stelzner, A. A rapid assay for evaluation of antiviral activity against coxsackie virus B3, influenza virus A, and herpes simplex virus type 1. *J. Virol. Methods* **95**, 133–143 (2001).

## Acknowledgements

Technical support by B. Jahn, L. Schumann, K. Bohn (Department of Virology and Antiviral Therapy, Jena University Hospital), S. Heiderstädt (Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Austria), and S. Linde (Center of Electron Microscopy, Jena University Hospital) is gratefully acknowledged. The authors thank A. Sauerbrei for his continuous and kind support of influenza research. This work was supported by the Austrian Science Fund (FWF: P24587) and the European Social Fund (ESF & TMWAT Project 2011 FGR 0137).

### Author Contributions

U.G., J.M.R. and M.S. conceived the work. U.G. contributed to the phytochemical investigation of sǎng bái pí. M.R., E.W. and A.H. performed antimicrobial tests. S.N. and M.R. carried out electron microscopy studies. J.K., J.M.R. and V.M. selected congeners of **5** and analysed the data. All authors contributed in interpretation of the results and the final writing of the manuscript. All authors have given approval to the final version of the paper.

### Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Grienke, U. *et al.* Discovery of prenylated flavonoids with dual activity against influenza virus and *Streptococcus pneumoniae*. *Sci. Rep.* **6**, 27156; doi: 10.1038/srep27156 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>